Determinant factors for first-line treatment choice and effectiveness in pediatric eosinophilic esophagitis: an analysis of the EUREOS EoE CONNECT registry.

Adolescent Dietary intervention Eosinophilic esophagitis Fibrosis Pediatrics Proton pump inhibitors Swallowed topical corticosteroids Therapeutic use

Journal

European journal of pediatrics

ISSN: 1432-1076

Titre abrégé: Eur J Pediatr

Pays: Germany

ID NLM: 7603873

Informations de publication

Date de publication:
31 May 2024

Historique:

received: 09 03 2024

accepted: 17 05 2024

revised: 03 05 2024

medline: 31 5 2024

pubmed: 31 5 2024

entrez: 31 5 2024

Statut: aheadofprint

Résumé

This study compared short-term effectiveness of proton pump inhibitors (PPI), swallowed topical corticosteroids (STC), and dietary therapies in reversing clinical and histological features in pediatric patients with eosinophilic esophagitits (EoE). Determinants for treatment choice and PPI therapy effectiveness were also assessed. A cross-sectional study analysis of patients under 18 years old recruited onto the multicenter EoE CONNECT registry was performed. Clinico-histological response was defined as symptomatic improvement plus a peak eosinophil count below 15 per high-power field after treatment. Effectiveness of first-line options used in monotherapy was compared. Overall, 393 patients (64% adolescents) receiving PPI, STC, or dietary monotherapy to induce EoE remission were identified. PPI was the preferred option (71.5%), despite STC providing the highest clinico-histological response rates (66%) compared to PPI (44%) and diet (42%). Logistic regression identified fibrotic features and recruitment at Italian sites independently associated to first-line STC treatment; age under 12 associated to dietary therapy over other options. Analysis of 262 patients in whom PPI effectiveness was evaluated after median (IQR) 96 (70-145) days showed that this effectiveness was significantly associated with management at pediatric facilities and use of high PPI doses. Among PPI responders, decrease in rings and structures in endoscopy from baseline was documented, with EREFS fibrotic subscore for rings also decreasing among responders (0.27 ± 0.63 vs. 0.05 ± 0.22, p < 0.001). Conclusion: Initial therapy choice for EoE depends on endoscopic phenotype, patient's age, and patients' origin. High PPI doses and treatment in pediatric facilities significantly determined effectiveness, and reversed fibrotic endoscopic features among responders. What is Known: • Proton pump inhibitors are widely used to induce and maintain remission in EoE in real practice, despite other first-line alternative therapies possibly providing higher effectiveness. What is New: • Proton pump inhibitors represent up to two-thirds of first-line monotherapies used to induce EoE remission in pediatric and adolescent patients with EoE. The choice of STC as first-line treatment for EoE was significantly associated with fibrotic features at baseline endoscopy and recruitment in Italian centers; age less than 12 years was associated with dietary therapy. • PPI effectiveness was found to be determined by use of high doses, attendance at pediatric facilities, presenting inflammatory instead of fibrotic or mixed phenotypes, and younger age. Among responders, PPI therapy reversed both inflammatory and fibrotic features of EoE after short-term treatment.

Identifiants

DOI: 10.1007/s00431-024-05618-z PMID: 38819501

pubmed: 38819501

doi: 10.1007/s00431-024-05618-z

pii: 10.1007/s00431-024-05618-z

doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Lucendo AJ, Molina-Infante J, Arias A et al (2017) Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United Eur Gastroenterol J 5:335–358. https://doi.org/10.1177/2050640616689525

doi: 10.1177/2050640616689525

Dellon ES, Liacouras CA, Molina-Infante J et al (2018) Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. Gastroenterology 155:1022–1033. https://doi.org/10.1053/j.gastro.2018.07.009

doi: 10.1053/j.gastro.2018.07.009 pubmed: 30009819

Feo-Ortega S, Lucendo AJ (2022) Evidence-based treatments for eosinophilic esophagitis: insights for the clinician. Ther Adv Gastroenterol 15:17562848211068664. https://doi.org/10.1177/17562848211068665

doi: 10.1177/17562848211068665

Schoepfer AM, Safroneeva E, Bussmann C et al (2013) Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology 145(1230–1236):e1-2. https://doi.org/10.1053/j.gastro.2013.08.015

doi: 10.1053/j.gastro.2013.08.015

Lipka S, Kumar A, Richter JE (2016) Impact of diagnostic delay and other risk factors on eosinophilic esophagitis phenotype and esophageal diameter. J Clin Gastroenterol 50:134–140. https://doi.org/10.1097/MCG.0000000000000297

doi: 10.1097/MCG.0000000000000297 pubmed: 25710524

Dellon ES, Kim HP, Sperry SLW et al (2014) A phenotypic analysis shows that eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc 79:577-585.e4. https://doi.org/10.1016/j.gie.2013.10.027

doi: 10.1016/j.gie.2013.10.027 pubmed: 24275329

Laserna-Mendieta EJ, Navarro P, Casabona-Francés S et al (2023) Differences between childhood- and adulthood-onset eosinophilic esophagitis: an analysis from the EoE connect registry. Dig Liver Dis 55:350–359. https://doi.org/10.1016/j.dld.2022.09.020

doi: 10.1016/j.dld.2022.09.020 pubmed: 36280437

Hoofien A, Dias JA, Malamisura M et al (2019) Pediatric eosinophilic esophagitis: results of the European Retrospective Pediatric Eosinophilic Esophagitis Registry (RetroPEER). J Pediatr Gastroenterol Nutr 68:552–558. https://doi.org/10.1097/MPG.0000000000002215

doi: 10.1097/MPG.0000000000002215 pubmed: 30540712

Hahn JW, Lee K, Shin JI et al (2023) Global incidence and prevalence of eosinophilic esophagitis, 1976–2022: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 21:3270–3284. https://doi.org/10.1016/j.cgh.2023.06.005

doi: 10.1016/j.cgh.2023.06.005 pubmed: 37331411

Arias Á, Lucendo AJ (2020) Epidemiology and risk factors for eosinophilic esophagitis: lessons for clinicians. Expert Rev Gastroenterol Hepatol 14:1069–1082. https://doi.org/10.1080/17474124.2020.1806054

doi: 10.1080/17474124.2020.1806054 pubmed: 32749898

Robson J, O’Gorman M, McClain A et al (2018) Incidence and prevalence of pediatric eosinophilic esophagitis in Utah based on a 5-year population-based study. Clin Gastroenterol Hepatol 17:107–114. https://doi.org/10.1016/j.cgh.2018.06.028

doi: 10.1016/j.cgh.2018.06.028 pubmed: 29935329

Arias Á, Lucendo AJ (2019) Incidence and prevalence of eosinophilic oesophagitis increase continiously in adults and children in Central Spain: a 12-year population-based study. Dig Liver Dis 51:55–62. https://doi.org/10.1016/j.dld.2018.07.016

doi: 10.1016/j.dld.2018.07.016 pubmed: 30115573

Visaggi P, Savarino E, Sciume G et al (2021) Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults. Therap Adv Gastroenterol 14:1756284820980860

doi: 10.1177/1756284820980860 pubmed: 33613690 pmcid: 7871287

Hirano I, Chan ES, Rank MA et al (2020) AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. Gastroenterology 158:1776–1786. https://doi.org/10.1053/j.gastro.2020.02.038

doi: 10.1053/j.gastro.2020.02.038 pubmed: 32359562

Visaggi P, Barberio B, Del Corso G et al (2023) Comparison of drugs for active eosinophilic oesophagitis: systematic review and network meta-analysis. Gut 72:2019–2030. https://doi.org/10.1136/gutjnl-2023-329873

doi: 10.1136/gutjnl-2023-329873 pubmed: 37491157

Tamarit-Sebastian S, Ferrer-Soler FM, Lucendo AJ (2022) Current options and investigational drugs for the treatment of eosinophilic esophagitis. Expert Opin Investig Drugs 1–18. https://doi.org/10.1080/13543784.2022.2033207

Aceves SS, Alexander JA, Baron TH et al (2022) Endoscopic approach to eosinophilic esophagitis: American Society for Gastrointestinal Endoscopy Consensus Conference. Gastrointest Endosc 96:576-592.e1. https://doi.org/10.1016/j.gie.2022.05.013

doi: 10.1016/j.gie.2022.05.013 pubmed: 35965102

Munoz-Persy M, Lucendo AJ (2018) Treatment of eosinophilic esophagitis in the pediatric patient: an evidence-based approach. Eur J Pediatr 177:649–663. https://doi.org/10.1007/s00431-018-3129-7

doi: 10.1007/s00431-018-3129-7 pubmed: 29549437

Laserna-Mendieta EJ, Casabona S, Guagnozzi D et al (2020) Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. Aliment Pharmacol Ther 52:798–807. https://doi.org/10.1111/apt.15957

doi: 10.1111/apt.15957 pubmed: 32677040

Tourlamain G, Garcia-Puig R, Gutiérrez-Junquera C et al (2020) Differences in management of eosinophilic esophagitis in Europe: an assessment of current practice. J Pediatr Gastroenterol Nutr 71:83–90. https://doi.org/10.1097/MPG.0000000000002672

doi: 10.1097/MPG.0000000000002672 pubmed: 32097371

Chang JW, Saini SD, Mellinger JL et al (2019) Management of eosinophilic esophagitis is often discordant with guidelines and not patient-centered: results of a survey of gastroenterologists. Dis Esophagus Off J Int Soc Dis Esophagus 1(32):doy133. https://doi.org/10.1093/dote/doy133

doi: 10.1093/dote/doy133

Hannan N, Steel A, McMillan SS, Tiralongo E (2020) Health service use and treatment choices for pediatric eosinophilic esophagitis: findings from a cross-sectional survey of Australian carers. Front Pediatr 8:147. https://doi.org/10.3389/fped.2020.00147

doi: 10.3389/fped.2020.00147 pubmed: 32363170 pmcid: 7180181

Zifman E, Banai H, Shamir R et al (2018) Practice differences in the diagnosis and management of eosinophilic esophagitis among adult and pediatric gastroenterologists in Israel. J Pediatr Gastroenterol Nutr 67:34–39. https://doi.org/10.1097/MPG.0000000000001909

doi: 10.1097/MPG.0000000000001909 pubmed: 29394215

Miehlke S, von Arnim U, Schlag C et al (2019) Clinical management of eosinophilic esophagitis — a nationwide survey among gastroenterologists in Germany. Z Gastroenterol 57:745–752. https://doi.org/10.1055/a-0885-1963

doi: 10.1055/a-0885-1963 pubmed: 31170743

Gutiérrez-Junquera C, Fernández-Fernández S, Domínguez-Ortega G et al (2023) Proton pump inhibitor therapy in pediatric eosinophilic esophagitis: predictive factors and long-term step-down efficacy. J Pediatr Gastroenterol Nutr 76(2):191–198. https://doi.org/10.1097/MPG.0000000000003660

doi: 10.1097/MPG.0000000000003660 pubmed: 36416845

Oliva S, Dias JA, Rea F et al (2022) Characterization of eosinophilic esophagitis from the European Pediatric Eosinophilic Esophagitis Registry (pEEr) of ESPGHAN. J Pediatr Gastroenterol Nutr 75:325–333. https://doi.org/10.1097/MPG.0000000000003530

doi: 10.1097/MPG.0000000000003530 pubmed: 35706095

Lucendo A, Santander C, Savarino E et al (2022) EoE CONNECT, the European registry of clinical, environmental and genetic determinants in eosinophilic esophagitis: Rationale, design and study protocol of a large-scale epidemiological study in Europe. Ther Adv Gastroenterol

Hirano I, Moy N, Heckman MG et al (2013) Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: Validation of a novel classification and grading system. Gut 62:489–495. https://doi.org/10.1136/gutjnl-2011-301817

doi: 10.1136/gutjnl-2011-301817 pubmed: 22619364

Lucendo AJ, Arias A, Molina-Infante J, Arias-Gonzalez L (2017) The role of endoscopy in eosinophilic esophagitis: from diagnosis to therapy. Expert Rev Gastroenterol Hepatol 11:1135–1149. https://doi.org/10.1080/17474124.2017.1367664

doi: 10.1080/17474124.2017.1367664 pubmed: 28803528

Armstrong D, Marshall JK, Chiba N (2005) Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults — update 2004. Can J Gastroenterol Hepatol 19:15–35. https://doi.org/10.1155/2005/836030

doi: 10.1155/2005/836030

Graham DY, Tansel A (2018) Interchangeable use of proton pump inhibitors based on relative potency. Clin Gastroenterol Hepatol 16:800–808.e7. https://doi.org/10.1016/j.cgh.2017.09.033

doi: 10.1016/j.cgh.2017.09.033 pubmed: 28964908

Klok RM, Postma MJ, van Hout BA, Brouwers JRBJ (2003) Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use. Aliment Pharmacol Ther 17:1237–1245. https://doi.org/10.1046/j.1365-2036.2003.01562.x

doi: 10.1046/j.1365-2036.2003.01562.x pubmed: 12755837

Kirchheiner J, Glatt S, Fuhr U et al (2009) Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol 65:19–31. https://doi.org/10.1007/s00228-008-0576-5

doi: 10.1007/s00228-008-0576-5 pubmed: 18925391

Carrascosa A, Yeste D, Moreno-Galdó A et al (2018) Índice de masa corporal e índice de masa triponderal de 1.453 niños no obesos ni malnutridos de la generación del milenio. Estudio longitudinal de Barcelona An Pediatría 89:137–143. https://doi.org/10.1016/j.anpedi.2017.12.016

doi: 10.1016/j.anpedi.2017.12.016

Carrascosa Lezcano A, Fernández-Cancio M, Yeste D et al. Milennials’ Grouth. Estudio longitudinal de crecimiento. Barcelona 1995–2017

Muftah M, Goldin AH, Barshop K et al (2024) Twice daily PPI induces higher remission rate in eosinophilic esophagitis than once daily regimen regardless of total daily dose. Am J Gastroenterol 119:991–995. https://doi.org/10.14309/ajg.0000000000002712

doi: 10.14309/ajg.0000000000002712 pubmed: 38314789

Laserna-Mendieta EJ, Casabona S, Savarino E et al (2020) Efficacy of therapy for eosinophilic esophagitis in real-world practice. Clin Gastroenterol Hepatol 18:2903-2911.e4. https://doi.org/10.1016/j.cgh.2020.01.024

doi: 10.1016/j.cgh.2020.01.024 pubmed: 31988045

Navarro P, Laserna-Mendieta EJ, Guagnozzi D et al (2021) Proton pump inhibitor therapy reverses endoscopic features of fibrosis in eosinophilic esophagitis. Dig Liver Dis 53:1479–1485. https://doi.org/10.1016/j.dld.2021.05.025

doi: 10.1016/j.dld.2021.05.025 pubmed: 34120859

Casabona-Francés S, Sanz-García A, Ortega GJ et al (2024) A new method to evaluate lower esophageal distension capacity in eosinophilic esophagitis by using functional lumen imaging probe (EndoFLIP™). Diagn Basel Switz 14:218. https://doi.org/10.3390/diagnostics14020218

doi: 10.3390/diagnostics14020218

Gonsalves N, Yang G-Y, Doerfler B et al (2012) Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology 142:1451–9.e1; quiz e14–15. https://doi.org/10.1053/j.gastro.2012.03.001

Laserna-Mendieta EJ, Navarro P, Casabona-Francés S et al (2024) Swallowed topical corticosteroids for eosinophilic esophagitis: Utilization and real-world efficacy from the EoE CONNECT registry. United Eur Gastroenterol J. https://doi.org/10.1002/ueg2.12533

doi: 10.1002/ueg2.12533

Miehlke S, Hruz P, Vieth M et al (2016) A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut 65:390–399. https://doi.org/10.1136/gutjnl-2014-308815

doi: 10.1136/gutjnl-2014-308815 pubmed: 25792708

Ma C, Schoepfer AM, Dellon ES et al (2021) Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). J Allergy Clin Immunol S0091674921010599. https://doi.org/10.1016/j.jaci.2021.07.001